- Home
- IFRX vs HOVR Comparison
IFRX vs HOVR Comparison
Compare IFRX & HOVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- HOVR
- Stock Information
- Founded
- IFRX 2007
- HOVR 2013
- Country
- IFRX Germany
- HOVR Canada
- Employees
- IFRX N/A
- HOVR N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- HOVR Blank Checks
- Sector
- IFRX Health Care
- HOVR Finance
- Exchange
- IFRX Nasdaq
- HOVR Nasdaq
- Market Cap
- IFRX 53.5M
- HOVR 62.1M
- IPO Year
- IFRX 2017
- HOVR N/A
- Fundamental
- Price
- IFRX $1.60
- HOVR $1.80
- Analyst Decision
- IFRX Strong Buy
- HOVR Strong Buy
- Analyst Count
- IFRX 4
- HOVR 1
- Target Price
- IFRX $7.75
- HOVR $2.00
- AVG Volume (30 Days)
- IFRX 577.2K
- HOVR 806.5K
- Earning Date
- IFRX 08-07-2025
- HOVR 08-22-2025
- Dividend Yield
- IFRX N/A
- HOVR N/A
- EPS Growth
- IFRX N/A
- HOVR N/A
- EPS
- IFRX N/A
- HOVR 0.12
- Revenue
- IFRX $191,224.00
- HOVR N/A
- Revenue This Year
- IFRX N/A
- HOVR N/A
- Revenue Next Year
- IFRX $1,336.36
- HOVR N/A
- P/E Ratio
- IFRX N/A
- HOVR $14.16
- Revenue Growth
- IFRX 54.36
- HOVR N/A
- 52 Week Low
- IFRX $0.71
- HOVR $0.24
- 52 Week High
- IFRX $2.82
- HOVR $2.52
- Technical
- Relative Strength Index (RSI)
- IFRX 89.35
- HOVR 59.61
- Support Level
- IFRX $0.82
- HOVR $1.46
- Resistance Level
- IFRX $0.96
- HOVR $1.90
- Average True Range (ATR)
- IFRX 0.11
- HOVR 0.13
- MACD
- IFRX 0.06
- HOVR 0.02
- Stochastic Oscillator
- IFRX 100.00
- HOVR 86.67
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About HOVR New Horizon Aircraft Ltd.
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and aiming to build a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, Floods and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.